BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. - Wikidata - awgldk - TriplyDB

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.

http://www.wikidata.org/entity/Q37708873

about

Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides.

P2860

Q45903443-00689156-BC7A-42A7-B30A-9BF81D5BE8AB

P2860

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.

http://www.wikidata.org/entity/Q37708873

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@en

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@nl

type

label

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@en

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@nl

prefLabel

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@en

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@nl

P1433

Q37708873-0A23DB8E-6CD3-4C57-BAF5-2C4BD6E94EF8

P1476

Q37708873-BE527613-4D5C-4B3B-A3E3-C0BA83BD78DB

P2093

Q37708873-02F9F1EF-EFE7-4C35-85EE-22A7F191F00C

Q37708873-038AB01E-37D6-476C-928C-03E7029A098F

Q37708873-0746FD92-1A7D-42B3-8340-80E61208EB0C

Q37708873-112985A5-43D2-4CAB-8382-A04FEEEE0F87

Q37708873-261A083D-BD06-4803-A60E-2B0AE9221996

Q37708873-31C0DB57-2AF5-4439-B7E2-B9E27B617D59

Q37708873-41AE1A14-7FD7-4027-9262-D2678DDCDFEF

Q37708873-4BAB1D2F-4E65-4B87-BB5C-8DEBAA7CE513

Q37708873-57503391-48DE-4E81-8B0C-7DEC09FABB59

Q37708873-71F885C7-B5CB-4A83-A4C7-54DFDD5A184A

P2860

Q37708873-00FA35CF-DBA1-4E59-A5E6-D7D631212870

Q37708873-02D02357-9D68-4B16-8497-9583ABB78DBB

Q37708873-0AE29CF4-5CA4-4F10-9E7F-14CE87DDBDF7

Q37708873-0B764A2E-4BDF-4EB5-B3E7-C54902B66901

Q37708873-0F2AB0E2-4463-4467-9790-EB88CB9828FE

Q37708873-1CFD3ECF-0906-48E0-815F-548AA9499CBC

Q37708873-1EB48E97-6016-4C8A-B6B7-3C60801B1E66

Q37708873-2A445500-7CB8-41D2-99D5-27A56A1AFC08

Q37708873-2BD25335-3B05-4A97-9F6E-15016C71606E

Q37708873-35C07492-1894-419B-A7F5-284923FCC3D1

P304

Q37708873-4E4EE3EA-44AD-4441-BC7F-A03BAE59CA75

P31

Q37708873-0F82B4A8-47AA-448D-A9EB-E5235F2A8C58

P356

Q37708873-A2EA4D24-9F04-4BFC-9E66-DD77D37D4DD2

P407

Q37708873-BBBEE26B-BE28-4E42-B2DD-320577498534

P433

Q37708873-EF595688-40DF-4794-A18E-6324009EB03E

P478

Q37708873-1232448C-DAA9-44BA-AEBB-70104332BBF1

P50

Q37708873-35B77FB2-58A9-4D63-A409-5ED4F40E2C09

P577

Q37708873-E2591433-1020-4CBC-AC39-2A20DF32F875

P698

Q37708873-A5AFBDAE-3C28-4318-8EBD-DCCE66BB61B0

P932

Q37708873-53A9EFCC-77B7-4CFC-A2D6-7F782B50A855

P356

ONCOTARGET.12112

P1433

P1476

BIM deletion polymorphisms in ...... er carriers of EGFR mutations.

@en

P2093

Andrés F Cardona

http://www.w3.org/2001/XMLSchema#string

Beatriz Wills

http://www.w3.org/2001/XMLSchema#string

Carlos Ortíz

http://www.w3.org/2001/XMLSchema#string

Carlos Vargas

http://www.w3.org/2001/XMLSchema#string

Christian Rolfo

http://www.w3.org/2001/XMLSchema#string

Claudio Martín

http://www.w3.org/2001/XMLSchema#string

Hernán Carranza

http://www.w3.org/2001/XMLSchema#string

Jorge Otero

http://www.w3.org/2001/XMLSchema#string

July Rodríguez

http://www.w3.org/2001/XMLSchema#string

Leonardo Rojas

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

P304

68933-68942

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12112

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27926478

http://www.w3.org/2001/XMLSchema#string

P932

5356601

http://www.w3.org/2001/XMLSchema#string